Commence the second Phase 1 multiple-ascending-dose study of SYN-020
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 4 Mar 2021
- Due
- 30 Sep 2021
- Delivered
- Q3 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“A second Phase 1 multiple-ascending-dose study is also expected to begin enrollment during the third quarter of 2021”
What we found
Evidence strength A What the grades mean
The 10-Q filed 2021-11-03 and later 10-K and 10-Q filings state the company initiated the Phase 1 MAD study of SYN-020 during Q3 2021, within the deadline period.
-
A Synthetic Biologics, Inc. 10-Q filed 2021-11-03
“During the third quarter of 2021 we initiated a Phase 1 clinical study evaluating multiple ascending doses (“MAD”) of SYN-020.” ✓ confirmed on the page
-
A Synthetic Biologics, Inc. 10-K filed 2022-03-16
“During the third quarter of 2021, we commenced enrollment, dosing and observation in a Phase 1, multiple ascending dose (“MAD”) clinical trial of SYN-020 in healthy, adult volunteers.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Commence
- Deliverable
- Second Phase 1 MAD study of SYN-020
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Synthetic Biologics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-TOVX-025108 · Corrections policy